Retinoid Therapy for Acute Promyelocytic Leukemia: A Coming of Age for the Differentiation Therapy of Malignancy

Editorials15 August 1992Retinoid Therapy for Acute Promyelocytic Leukemia: A Coming of Age for the Differentiation Therapy of MalignancyDavid R. Parkinson, MD, Malcolm A. Smith, MD, PhDDavid R. Parkinson, MDSearch for more papers by this author, Malcolm A. Smith, MD, PhDSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-117-4-338 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptIn this issue of Annals, Frankel and colleagues (1) describe a syndrome that developed in patients with acute promyelocytic leukemia during treatment with all-trans retinoic acid (1). The description of this dramatic syndrome provides an opportunity to review the larger significance of a remarkable new class of drugs, retinoids, and of differentiation therapy for malignancy.The unfolding story of the use of retinoic acid for successful remission induction in patients with acute promyelocytic leukemia is instructive and is a confirmation of the coming of age of the differentiation therapy of malignancy. Long a goal of cancer therapists, it is...References1. FrankelEardleyLauwersWeissWarrell SAGMR. The retinoic acid syndrome in acute promyelocytic leukemia. Ann Intern Med. 1992;117:292-6. LinkGoogle Scholar2. BreitmanSelonicCollins TSS. Induction of differentiation of the human promyelocytic leukemia cell line (HL-60) by retinoic acid. Proc Natl Acad Sci USA. 1980;77:2936-40. CrossrefMedlineGoogle Scholar3. SmithParkinsonChesonFriedman MDBM. Retinoids in cancer therapy. J Clin Oncol. 1992;10:839-64. CrossrefMedlineGoogle Scholar4. HuangYeChenChaiLuZhoa MYSJJL. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood. 1988;72:567-72. CrossrefMedlineGoogle Scholar5. CastaigneChomienneDanielBalleriniBerger SCMPR. All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results. Blood. 1990;76:1704-9. CrossrefMedlineGoogle Scholar6. WarrellFrankelMillerScheinbergItri RSWDL. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). N Engl J Med. 1991;324:1385-93. CrossrefMedlineGoogle Scholar7. de TheLavauMarchioChomienneDegosDejean HCACLA. The PML-RARα fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR. Cell. 1991;66:675-84. CrossrefMedlineGoogle Scholar8. KakizukaMillerUmesono AWK. Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RARα with a novel putative transcription factor, PML. Cell. 1991;66:663-74. CrossrefMedlineGoogle Scholar9. BertramKolonelMeyskens JLF. Rationale and strategies for chemoprevention of cancer in humans. Cancer Res. 1987;47:3012-31. MedlineGoogle Scholar10. GarewalMeyskens HF. Retinoids and carotenoids in the prevention of oral cancer: a critical appraisal. Cancer Epidemiology, Biomarkers, and Prevention. 1992;1:155-9. MedlineGoogle Scholar11. ConleyWuEgorinHodgesSinibaldiVan Echo BSMSVD. Phase I and pharmacokinetic trial of oral all-trans retinoic acid in patients with solid tumors [Abstract]. Proc Am Soc Clin Oncol. 1992;11:113. Google Scholar12. PitotRubinO'Connell HJM. Phase I study of all-trans retinoic acid in solid tumors [Abstract]. Proc Am Soc Clin Oncol. 1992;11:126. Google Scholar13. MuindiFrankelMiller JSW. Continuous treatment with all-trans retinoic acid causes a progressive reduction in plasma drug concentrations: implications for relapse and retinoid "resistance" in patients with acute promyelocytic leukemia. Blood. 1992;79:299-303. CrossrefMedlineGoogle Scholar14. SmithAdamsonBalis MPF. Phase I and pharmacokinetic evaluation of all-trans retinoic acid in pediatric patients. J Clin Oncol. 1992;[In press]. CrossrefGoogle Scholar15. FrancisRigasMuindiKrisYoungWarrell PJJMCR. Modulation of all-trans retinoic acid (RA) pharmacokinetics by a cytochrome P-450 enzyme system inhibitor. Proc Am Soc Clin Oncol. 1992;11:108. Google Scholar16. HassanRees HJ. Retinoic acid alone and in combination with cytosine arabinoside induces differentiation of human myelomonocytic and monoblastic leukaemic cells. Hematol Oncol. 1988;6:39-45. CrossrefMedlineGoogle Scholar17. BreitmanHe TR. Combinations of retinoic acid with either sodium butyrate, dimethylsulfoxide, or hexamethylene bisacetamide synergistically induce differentiation of the human myeloid leukemia cell line HL60. Cancer Res. 1990;50:6268-73. MedlineGoogle Scholar18. LippmanKavanaghParedes-Espinoza SJM. 13-Cis-retinoic acid plus interferon-alpha 2a: highly acute systemic therapy for squamous cell carcinoma of the cervix. J Natl Cancer Inst. 1992;84:241-5. CrossrefMedlineGoogle Scholar19. LippmanParkinsonItri SDL. 13-cis-retinoic acid and interferon alpha-2a: effective combination therapy for advanced squamous cell carcinoma of the skin. J Natl Cancer Inst. 1992;84:235-41. CrossrefMedlineGoogle Scholar20. RackowAstiz EM. Pathophysiology and treatment of septic shock. JAMA. 1991;266:548-54. CrossrefMedlineGoogle Scholar21. SiegelPuri JR. Interleukin-2 toxicity. J Clin Oncol. 1991;9:694-704. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: David R. Parkinson, MD; Malcolm A. Smith, MD, PhDAffiliations: Cancer Therapy Evaluation Program National Cancer Institute Bethesda, MD 20892 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byContinuous hemofiltration in the management of ‘retinoic acid syndrome’RetinoidsPrefaceRetinoids and apoptosis in cancer therapyRole of Vitamin A and Its Derivatives in the Treatment of Human CancerReverse Transformation, Genome Exposure, and Cancer 15 August 1992Volume 117, Issue 4Page: 338-340KeywordsDrug therapyDrugsRetinoic acidRetinoids ePublished: 1 December 2008 Issue Published: 15 August 1992 PDF downloadLoading ...